PAC-1 and isatin derivatives are weak matrix metalloproteinase inhibitors
- 1 October 2014
- journal article
- Published by Elsevier in Biochimica et Biophysica Acta (BBA) - General Subjects
- Vol. 1840 (10) , 3162-3169
Abstract
No abstract availableKeywords
Funding Information
- Norwegian Cancer Society
- Erna and Olav Aakre Foundation for Cancer
- Tromsø Forskningsstiftelse
- The Research Council of Norway (185222)
This publication has 51 references indexed in Scilit:
- Targeting caspases in cancer therapeuticsBiological Chemistry, 2013
- Parallel Synthesis and Biological Evaluation of 837 Analogues of Procaspase-Activating Compound 1 (PAC-1)ACS Combinatorial Science, 2011
- Regulation of Caspases in the Nervous System2011
- Procaspase-activating compound 1 induces a caspase-3-dependent cell death in cerebellar granule neuronsToxicology and Applied Pharmacology, 2010
- DNA damage, neuronal and glial cell death and neurodegenerationApoptosis, 2010
- The Role of Apoptosis in Cancer Development and Treatment: Focusing on the Development and Treatment of Hematologic MalignanciesCurrent Pharmaceutical Design, 2010
- Procaspase-3 Activation as an Anti-Cancer Strategy: Structure−Activity Relationship of Procaspase-Activating Compound 1 (PAC-1) and Its Cellular Co-Localization with Caspase-3Journal of Medicinal Chemistry, 2009
- PAC-1 Activates Procaspase-3 in Vitro through Relief of Zinc-Mediated InhibitionJournal of Molecular Biology, 2009
- The Hallmarks of CancerCell, 2000
- Apoptosis and Predisposition To Oral CancerCritical Reviews in Oral Biology & Medicine, 1999